- Home
- MITQ vs APVO Comparison
MITQ vs APVO Comparison
Compare MITQ & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITQ
- APVO
- Stock Information
- Founded
- MITQ N/A
- APVO 2016
- Country
- MITQ United States
- APVO United States
- Employees
- MITQ N/A
- APVO N/A
- Industry
- MITQ Telecommunications Equipment
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- MITQ Telecommunications
- APVO Health Care
- Exchange
- MITQ Nasdaq
- APVO Nasdaq
- Market Cap
- MITQ 5.5M
- APVO 4.1M
- IPO Year
- MITQ 2021
- APVO N/A
- Fundamental
- Price
- MITQ $0.65
- APVO $3.23
- Analyst Decision
- MITQ
- APVO Strong Buy
- Analyst Count
- MITQ 0
- APVO 1
- Target Price
- MITQ N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- MITQ 9.8M
- APVO 6.7M
- Earning Date
- MITQ 05-15-2025
- APVO 08-07-2025
- Dividend Yield
- MITQ N/A
- APVO N/A
- EPS Growth
- MITQ N/A
- APVO N/A
- EPS
- MITQ N/A
- APVO N/A
- Revenue
- MITQ $18,613,000.00
- APVO N/A
- Revenue This Year
- MITQ N/A
- APVO N/A
- Revenue Next Year
- MITQ N/A
- APVO N/A
- P/E Ratio
- MITQ N/A
- APVO N/A
- Revenue Growth
- MITQ N/A
- APVO N/A
- 52 Week Low
- MITQ $0.50
- APVO $2.81
- 52 Week High
- MITQ $1.55
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- MITQ 54.04
- APVO 34.28
- Support Level
- MITQ $0.61
- APVO $2.81
- Resistance Level
- MITQ $0.71
- APVO $13.11
- Average True Range (ATR)
- MITQ 0.06
- APVO 1.10
- MACD
- MITQ 0.01
- APVO 0.30
- Stochastic Oscillator
- MITQ 20.65
- APVO 4.08
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.